Dr. Doyle is an epidemiologist and health services researcher who specializes in studying the risks, benefits, and value of healthcare interventions. He has over 25 years of experience in conducting research covering specialties such as pharmacoepidemiology, health economics & outcomes research, and real-world evidence. He has applied these disciplines to develop novel models of market access for biopharmaceuticals, including outcomes-based agreements and innovative financing to support value-based healthcare initiatives. Dr. Doyle has published over 200 abstracts and peer-reviewed articles, with special concentration in oncology. He serves as the co-chair of the Health Economic Impact Steering Committee for the Alliance for Regenerative Medicine where he focuses on the value assessment of cell and gene therapy. Dr. Doyle frequently gives presentations and lectures on the above areas of expertise in both commercial and academic settings internationally. Dr. Doyle has served on the faculty at Columbia University's Mailman School of Public Health since 2005.
